{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:02:30Z","timestamp":1740142950602,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00508-020-01791-x","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T17:03:07Z","timestamp":1609779787000},"page":"515-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical-Pathological Conference Series from the Medical University of Graz"],"prefix":"10.1007","volume":"133","author":[{"given":"Elisabeth","family":"Fabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Kump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp U.","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Kl\u00f6ppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer W.","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Moinfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Sch\u00f6fl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fickert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenter J.","family":"Krejs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"1791_CR1","unstructured":"TGA Consumer Medical Information (CMI), May 2017, Cosudex\u00ae 50mg Tablets. AstraZeneca Pty Ltd"},{"key":"1791_CR2","unstructured":"TGA Consumer Medical Information (CMI), June 2016, Lucrin\u00ae 5\u202fmg\/ml injection. AbbVie Pty Ltd"},{"key":"1791_CR3","unstructured":"TGA Consumer Medical Information (CMI), June 2019, XGEVA\u00ae. Amgen Australia Pty Ltd"},{"issue":"5B","key":"1791_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(87)90425-6","volume":"82","author":"GJ Krejs","year":"1987","unstructured":"Krejs\u00a0GJ. VIPoma syndrome. Am J Med. 1987;82(5B):37\u201348.","journal-title":"Am J Med"},{"key":"1791_CR5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1749-6632.1988.tb27003.x","volume":"527","author":"GJ Krejs","year":"1988","unstructured":"Krejs\u00a0GJ. Effect of vasoactive intestinal peptide in man. Ann N Y Acad Sci. 1988;527:501\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"1791_CR6","volume-title":"Digestive system tumors. WHO Classification of tumors","year":"2019","unstructured":"International Agency for Research on Cancer, editor. Digestive system tumors. WHO Classification of tumors. 5th\u00a0ed. Lyon: International Agency for Research on Cancer; 2019.","edition":"5"},{"key":"1791_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-213016","author":"A Fujiya","year":"2015","unstructured":"Fujiya\u00a0A, Kato\u00a0M, Shibata\u00a0T, Sobajima\u00a0H. VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation. BMJ Case Rep. 2015; https:\/\/doi.org\/10.1136\/bcr-2015-213016.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1791_CR8","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41467-020-15426-2","volume":"11","author":"V Faugeroux","year":"2020","unstructured":"Faugeroux\u00a0V, Pailler\u00a0E, Oulhen\u00a0M, Deas\u00a0O, Brulle-Soumare\u00a0L, Hervieu\u00a0C, et al. Genetic characterization of a\u00a0unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat Commun. 2020;11(1):1884.","journal-title":"Nat Commun"},{"issue":"9747","key":"1791_CR9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono\u00a0JS, Oudard\u00a0S, Ozguroglu\u00a0M, Hansen\u00a0S, Machiels\u00a0JP, Kocak\u00a0I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a\u00a0randomised open-label trial. Lancet. 2010;376(9747):1147\u201354.","journal-title":"Lancet"},{"issue":"21","key":"1791_CR10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono\u00a0JS, Logothetis\u00a0CJ, Molina\u00a0A, Fizazi\u00a0K, North\u00a0S, Chu\u00a0L, et\u00a0al. Abiraterone and increased survival in metastatic prostate cancer. N\u00a0Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"5","key":"1791_CR11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer\u00a0TM, Armstrong\u00a0AJ, Rathkopf\u00a0DE, Loriot\u00a0Y, Sternberg\u00a0CN, Higano\u00a0CS, et\u00a0al. Enzalutamide in metastatic prostate cancer before chemotherapy. N\u00a0Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"5","key":"1791_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff\u00a0PW, Higano\u00a0CS, Shore\u00a0ND, Berger\u00a0ER, Small\u00a0EJ, Penson\u00a0DF, et al. Sipuleucel\u2011T immunotherapy for castration-resistant prostate cancer. N\u00a0Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"1791_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker\u00a0C, Nilsson\u00a0S, Heinrich\u00a0D, Helle\u00a0SI, O\u2019Sullivan\u00a0JM, Foss\u00e5\u00a0SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N\u00a0Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"15","key":"1791_CR14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak\u00a0DP, Tangen\u00a0CM, Hussain\u00a0MH, Lara\u00a0PN Jr, Jones\u00a0JA, Taplin\u00a0ME, et\u00a0al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N\u00a0Engl J Med. 2004;351(15):1513\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"1791_CR15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran\u00a0H, Prandi\u00a0D, Mosquera\u00a0JM, Benelli\u00a0M, Puca\u00a0L, Cyrta\u00a0J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305.","journal-title":"Nat Med"},{"issue":"6","key":"1791_CR16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran\u00a0H, Rickman\u00a0DS, Park\u00a0K, Chae\u00a0SS, Sboner\u00a0A, MacDonald\u00a0TY, et\u00a0al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487\u201395.","journal-title":"Cancer Discov"},{"issue":"6","key":"1791_CR17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein\u00a0JI, Amin\u00a0MB, Beltran\u00a0H, Lotan\u00a0TL, Mosquera\u00a0JM, Reuter\u00a0VE, et\u00a0al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756\u201367.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1791_CR18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1677\/erc.1.00876","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti\u00a0A, Mosca\u00a0A, Tucci\u00a0M, Terrone\u00a0C, Torta\u00a0M, Tarabuzzi\u00a0R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12(1):109\u201317.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1791_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/CBM-2011-0198","volume":"8","author":"D Sarkar","year":"2011","unstructured":"Sarkar\u00a0D, Singh\u00a0SK, Mandal\u00a0AK, Agarwal\u00a0MM, Mete\u00a0UK, Kumar\u00a0S, et\u00a0al. Plasma chromogranin a: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark. 2011;8(2):81\u20137.","journal-title":"Cancer Biomark"},{"issue":"3","key":"1791_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1530\/ERC-14-0071","volume":"21","author":"SL Burgio","year":"2014","unstructured":"Burgio\u00a0SL, Conteduca\u00a0V, Menna\u00a0C, Carretta\u00a0E, Rossi\u00a0L, Bianchi\u00a0E, et\u00a0al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer. 2014;21(3):487\u201393.","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"1791_CR21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/pros.22890","volume":"74","author":"V Conteduca","year":"2014","unstructured":"Conteduca\u00a0V, Burgio\u00a0SL, Menna\u00a0C, Carretta\u00a0E, Rossi\u00a0L, Bianchi\u00a0E, et\u00a0al. Chromogranin A is a\u00a0potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate. 2014;74(16):1691\u20136.","journal-title":"Prostate"},{"issue":"23","key":"1791_CR22","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1158\/0008-5472.CAN-08-2229","volume":"68","author":"X Deng","year":"2008","unstructured":"Deng\u00a0X, Liu\u00a0H, Huang\u00a0J, Cheng\u00a0L, Keller\u00a0ET, Parsons\u00a0SJ, et\u00a0al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res. 2008;68(23):9663\u201370.","journal-title":"Cancer Res"},{"issue":"2","key":"1791_CR23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2004.09.007","volume":"47","author":"N Vashchenko","year":"2005","unstructured":"Vashchenko\u00a0N, Abrahamsson\u00a0PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47(2):147\u201355.","journal-title":"Eur Urol"},{"issue":"11 Suppl Int","key":"1791_CR24","first-page":"141","volume":"28","author":"A Mosca","year":"2005","unstructured":"Mosca\u00a0A, Berruti\u00a0A, Russo\u00a0L, Torta\u00a0M, Dogliotti\u00a0L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J\u00a0Endocrinol Invest. 2005;28(11 Suppl Int):141\u20135.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1791_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.pcan.4500922","volume":"10","author":"EC Nelson","year":"2007","unstructured":"Nelson\u00a0EC, Cambio\u00a0AJ, Yang\u00a0JC, Ok\u00a0JH, Lara\u00a0PN Jr, Evans\u00a0CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(1):6\u201314.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1791_CR26","first-page":"90","volume":"5","author":"CD Hu","year":"2015","unstructured":"Hu\u00a0CD, Choo\u00a0R, Huang\u00a0J. Neuroendocrine differentiation in prostate cancer: a\u00a0mechanism of radioresistance and treatment failure. Front Oncol. 2015;5:90.","journal-title":"Front Oncol"},{"issue":"3","key":"1791_CR27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.cdd.4401375","volume":"11","author":"K Vanoverberghe","year":"2004","unstructured":"Vanoverberghe\u00a0K, Vanden Abeele\u00a0F, Mariot\u00a0P, Lepage\u00a0G, Roudbaraki\u00a0M, Bonnal\u00a0JL, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 2004;11(3):321\u201330.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1791_CR28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/ERC-07-0061","volume":"14","author":"TC Yuan","year":"2007","unstructured":"Yuan\u00a0TC, Veeramani\u00a0S, Lin\u00a0MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14(3):531\u201347.","journal-title":"Endocr Relat Cancer"},{"key":"1791_CR29","first-page":"1","volume-title":"Vasoactive intestinal peptide","author":"V Mutt","year":"1982","unstructured":"Mutt\u00a0V. Isolation and structure of vasoactive intestinal polypeptide from various species. In: Said\u00a0SI, editor. Vasoactive intestinal peptide. New York: Raven Press; 1982. pp.\u00a01\u201310."},{"issue":"3951","key":"1791_CR30","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","volume":"169","author":"SI Said","year":"1970","unstructured":"Said\u00a0SI, Mutt\u00a0V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217\u20138.","journal-title":"Science"},{"issue":"5235","key":"1791_CR31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/225863a0","volume":"225","author":"SI Said","year":"1970","unstructured":"Said\u00a0SI, Mutt\u00a0V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 1970;225(5235):863\u20134.","journal-title":"Nature"},{"issue":"4","key":"1791_CR32","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0016-5085(19)32802-1","volume":"67","author":"M Grossman","year":"1974","unstructured":"Grossman\u00a0M, Brown\u00a0JC, Said\u00a0S, Adelson\u00a0J, Rothman\u00a0SS, Li\u00a0TM, et\u00a0al. Candidate hormones of the gut. Gastroenterology. 1974;67(4):730\u201355.","journal-title":"Gastroenterology"},{"issue":"3","key":"1791_CR33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0002-9343(58)90075-5","volume":"25","author":"JV Verner","year":"1958","unstructured":"Verner\u00a0JV, Morrison\u00a0AB. Islet cell tumor and a\u00a0syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25(3):374\u201380.","journal-title":"Am J Med"},{"issue":"4","key":"1791_CR34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00000658-195510000-00015","volume":"142","author":"R Zollinger","year":"1955","unstructured":"Zollinger\u00a0R, Ellison\u00a0EH. Primary peptic ulceration of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142(4):709\u201323.","journal-title":"Ann Surg"},{"issue":"7819","key":"1791_CR35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(73)91947-8","volume":"2","author":"SR Bloom","year":"1973","unstructured":"Bloom\u00a0SR, Polak\u00a0JM, Pearse\u00a0AG. Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet. 1973;2(7819):14\u20136.","journal-title":"Lancet"},{"issue":"4","key":"1791_CR36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJM197507242930401","volume":"293","author":"SI Said","year":"1975","unstructured":"Said\u00a0SI, Faloona\u00a0GR, Harvey\u00a0S, Deon\u00a0H, Ford\u00a0WT. Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N\u00a0Engl J Med. 1975;293(4):155\u201360.","journal-title":"N Engl J Med"},{"issue":"4","key":"1791_CR37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1677\/ERC-10-0152","volume":"17","author":"MB Niederle","year":"2010","unstructured":"Niederle\u00a0MB, Hackl\u00a0M, Kaserer\u00a0K, Niederle\u00a0B. Gastroenteropancreatic neuroendocrine tumors: the current incidence and staging based on the WHO and European Neuroendocrine tumor Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909\u201318.","journal-title":"Endocr Relat Cancer"},{"key":"1791_CR38","first-page":"257","volume-title":"Gastrointestinal disease","author":"GJ Krejs","year":"1983","unstructured":"Krejs\u00a0GJ, Fordtran\u00a0JS. Diarrhea. In: Sleisenger\u00a0M, Fordtran\u00a0JS, editors. Gastrointestinal disease. 3rd\u00a0ed. Philadelphia: WB Saunders; 1983. pp.\u00a0257\u201380.","edition":"3"},{"issue":"3","key":"1791_CR39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/00365528109181992","volume":"16","author":"M Holm-Bentzen","year":"1981","unstructured":"Holm-Bentzen\u00a0M, Christiannsen\u00a0J, Petersen\u00a0B, Fahrenkrug\u00a0J, Schultz\u00a0A, Kirkegaard\u00a0P. Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. Scand J Gastroent. 1981;16(3):429\u201332.","journal-title":"Scand J Gastroent"},{"issue":"24","key":"1791_CR40","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM198312153092403","volume":"309","author":"MG Kane","year":"1983","unstructured":"Kane\u00a0MG, O\u2019Dorisio\u00a0TM, Krejs\u00a0GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N\u00a0Engl J Med. 1983;309(24):1482\u20135.","journal-title":"N Engl J Med"},{"key":"1791_CR41","first-page":"141","volume-title":"Secretory diarrhea","author":"GJ Krejs","year":"1980","unstructured":"Krejs\u00a0GJ, Hendler\u00a0RS, Fordtran\u00a0JS. Diagnostic and pathophysiologic studies in patients with chronic diarrhea. In: Field\u00a0M, editor. Secretory diarrhea. Bethesda: American Physiologic Society; 1980. pp.\u00a0141\u201351."},{"issue":"2","key":"1791_CR42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0196-9781(84)90218-3","volume":"5","author":"GJ Krejs","year":"1984","unstructured":"Krejs\u00a0GJ. Effect of somatostatin infusion on VIP-induced transport changes in the human jejunum. Peptides. 1984;5(2):271\u20136.","journal-title":"Peptides"},{"issue":"5","key":"1791_CR43","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1172\/JCI109051","volume":"61","author":"GJ Krejs","year":"1978","unstructured":"Krejs\u00a0GJ, Barkley\u00a0RM, Read\u00a0NW, Fordtran\u00a0JS. Intestinal secretion induced by vasoactive intestinal polypeptide. A comparison with cholera toxin in the canine jejunum in vivo. J\u00a0Clin Invest. 1978;61(5):1337\u201345.","journal-title":"J Clin Invest"},{"issue":"3","key":"1791_CR44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/0003-4819-103-3-363","volume":"103","author":"WC Santangelo","year":"1985","unstructured":"Santangelo\u00a0WC, O\u2019Dorisio\u00a0TM, Kim\u00a0JG, Severino\u00a0G, Krejs\u00a0GJ. Pancreatic cholera syndrome: effect of a\u00a0synthetic somatostatin analog on intestinal water and ion transport. Ann Int Med. 1985;103(3):363\u20137.","journal-title":"Ann Int Med"},{"issue":"3","key":"1791_CR45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2012.06.008","volume":"41","author":"E Fabian","year":"2012","unstructured":"Fabian\u00a0E, Kump\u00a0P, Krejs\u00a0GJ. Diarrhea caused by circulating agents. Gastroenterol Clin North Am. 2012;41(3):603\u201310.","journal-title":"Gastroenterol Clin North Am"},{"issue":"28","key":"1791_CR46","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke\u00a0A, M\u00fcller\u00a0HH, Schade-Brittinger\u00a0C, Klose\u00a0KJ, Barth\u00a0P, Wied\u00a0M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a\u00a0report from the PROMID Study Group. J\u00a0Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1791_CR47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin\u00a0ME, Pavel\u00a0M, \u0106wik\u0142a\u00a0JB, Phan\u00a0AT, Raderer\u00a0M, Sedl\u00e1\u010dkov\u00e1\u00a0E, et\u00a0al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N\u00a0Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med"},{"issue":"18","key":"1791_CR48","first-page":"5969","volume":"50","author":"JC Reubi","year":"1990","unstructured":"Reubi\u00a0JC, Kvols\u00a0LK, Waser\u00a0B, Nagorney\u00a0DM, Heitz\u00a0PU, Charbonneau\u00a0JW, et\u00a0al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969\u201377.","journal-title":"Cancer Res"},{"issue":"28","key":"1791_CR49","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"IM Modlin","year":"2009","unstructured":"Modlin\u00a0IM, Oberg\u00a0K, Chung\u00a0DC, Jensen\u00a0RT, de Herder\u00a0WW, Thakker\u00a0RV, et\u00a0al. Gastroenteropancreatic neuroendocrine tumors. J\u00a0Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1791_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg\u00a0J, El-Haddad\u00a0G, Wolin\u00a0E, Hendifar\u00a0A, Yao\u00a0J, Chasen\u00a0B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. NETTER\u20111 Trial Investigators. N\u00a0Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"6","key":"1791_CR51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond\u00a0E, Dahan\u00a0L, Raoul\u00a0JL, Bang\u00a0YJ, Borbath\u00a0I, Lombard-Bohas\u00a0C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N\u00a0Engl J Med. 2011;364(6):501\u201313.","journal-title":"N Engl J Med"},{"issue":"10022","key":"1791_CR52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao\u00a0JC, Fazio\u00a0N, Singh\u00a0S, Buzzoni\u00a0R, Carnaghi\u00a0C, Wolin\u00a0E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumors of the lung, gastrointestinal tract (RADIANT-4): a\u00a0randomized, placebo-controlled phase 3 study. Lancet. 2016;387(10022):968\u201377.","journal-title":"Lancet"},{"issue":"12","key":"1791_CR53","doi-asserted-by":"crossref","first-page":"e0143822","DOI":"10.1371\/journal.pone.0143822","volume":"10","author":"S Krug","year":"2015","unstructured":"Krug\u00a0S, Boch\u00a0M, Daniel\u00a0H, Nimphius\u00a0W, M\u00fcller\u00a0D, Michl\u00a0P, et al. Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms: predictive and prognostic markers for treatment stratification. PLoS ONE. 2015;10(12):e143822.","journal-title":"PLoS ONE"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-020-01791-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T10:49:25Z","timestamp":1620816565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-020-01791-x"}},"subtitle":["Case No\u00a0173: A\u00a077-year-old patient with adenocarcinoma of the prostate, liver metastases and watery diarrhea"],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":53,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01791-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"27 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0Fabian, P.\u00a0Kump, D.\u00a0Schiller, I.\u00a0Brcic, C.\u00a0Gruber, P.U.\u00a0Heitz, G.\u00a0Kl\u00f6ppel, R.W.\u00a0Lipp, F.\u00a0Moinfar, R.\u00a0Sch\u00f6fl, P.\u00a0Fickert, and G.J.\u00a0Krejs declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}